Teva Secures Global Rights to Polpharma’s Ocrevus Biosimilar
Event summary
- Teva gains exclusive global rights to commercialize Polpharma’s biosimilar candidate for Ocrevus (ocrelizumab) in multiple sclerosis, including both intravenous and subcutaneous formulations.
- Polpharma retains development and manufacturing responsibilities; Teva handles regulatory submissions and commercialization in key markets including the U.S., Europe, and Brazil.
- The deal aligns with Teva’s Pivot to Growth strategy, expanding its biosimilars pipeline through strategic collaborations.
The big picture
This agreement underscores Teva’s push into high-value biologics as part of its Pivot to Growth strategy. The deal reflects a broader industry trend toward strategic collaborations to expand biosimilars pipelines and challenge incumbent treatments like Roche’s Ocrevus, which generated over $6 billion in sales in 2025. Success hinges on Teva’s ability to navigate regulatory hurdles and commercialize the biosimilar efficiently.
What we're watching
- Regulatory Approval
- The pace at which Polpharma’s biosimilar candidate secures regulatory approvals will determine Teva’s commercialization timeline.
- Market Competition
- How Teva positions this biosimilar against Roche’s Ocrevus in key markets could impact its market share and pricing power.
- Execution Risk
- Whether Teva can effectively leverage its global commercial footprint to drive adoption of the biosimilar, especially in competitive therapeutic areas.
Related topics